Related Experiment Video
Updated: Jun 13, 2026
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Structure-Based Discovery of Potent BCL-XL Inhibitors through Rescaffolding
Matyas Pal Timari1,2, Attila Paczal1, Andras Herner1
1Servier Research Institute of Medicinal Chemistry, Záhony utca 7, Budapest H-1031, Hungary.
Researchers developed novel BCL-XL inhibitors targeting cancer
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Evasion of apoptosis is a key characteristic of cancer development.
- Dysregulation of BCL-XL, a BCL-2 family protein, is implicated in various cancers.
Purpose of the Study:
- To design and synthesize novel BCL-XL inhibitors.
- To optimize inhibitors for high binding affinity and further modification.
- To evaluate their therapeutic potential in cancer treatment.
Main Methods:
- Chemical synthesis of novel mono- and bicyclic BCL-XL inhibitors.
- Assessment of binding affinities and cellular potency in BCL-XL-dependent cell lines.
- In vivo evaluation using xenograft tumor models.
Main Results:
- Novel inhibitors with unique mono- and bicyclic cores were synthesized.
- Lead compounds demonstrated picomolar binding affinities and potent cellular activity.
- Significant tumor growth inhibition was observed in xenograft studies.
Conclusions:
- The novel BCL-XL inhibitors show promise as therapeutic agents.
- Targeting the intrinsic apoptotic pathway via BCL-XL inhibition is a viable cancer treatment strategy.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
05:55Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019